Endometriosis — Body Handbook

Healthcare · §619

Endometriosis

Endometriosis is tissue that behaves like the lining of the uterus, growing where it shouldn't — on the ovaries, the bowel, the bladder, the pelvic walls. It bleeds every month at those sites with nowhere to go, scarring everything around it. About one in ten women have it, and on average it takes them six to ten years to get diagnosed. Most of those years are spent being told that severe period pain is just what periods are. It isn't. The point of this entry is to put the symptom pattern in your head — for yourself, your partner, your sister, your daughter — so that the next time someone you know is missing work every month because of their period, you know what to ask about.

Know · As-needed Evidence Strong Chapter Healthcare

A common, treatable condition that the medical system has historically been bad at catching. Continuous hormonal therapy controls pain in most women within a few months; surgery and newer hormone-blocker pills cover the cases it doesn't. The hard part is almost never the treatment — it's getting taken seriously long enough to be offered one.

The lining of the uterus — the endometrium — is built up by oestrogen each month and shed as a period. In endometriosis, tissue that looks and behaves almost exactly like that lining grows in the wrong place. Common spots: the surface of the ovaries (where it forms cysts full of old blood, called endometriomas), the ligaments that hold the uterus, the wall of the rectum, the outside of the bladder, the floor of the pelvis. Wherever it lands, it still responds to the monthly hormone cycle. It still bleeds. But the blood has nowhere to drain, so it pools, inflames the tissue around it, and over time builds scar tissue that glues organs to each other.

How it gets there is still partly an open question. The most widely accepted explanation, proposed by John Sampson nearly a century ago, is retrograde menstruation: during a period, some menstrual blood flows backward through the fallopian tubes into the pelvis instead of down and out, carrying living fragments of endometrial tissue with it Sampson 1927. Most women have some retrograde flow; only about one in ten develops persistent disease, so something else — immune function, genetics, hormone responsiveness, local inflammation — decides who the fragments take root in Zondervan et al. 2020.

The two things to take from the mechanism: it's a real, physical, definable disease — not a pain syndrome, not a psychiatric condition — and once it's established, the monthly hormone cycle keeps feeding it. That second point is why most treatment works by suppressing periods.

How common, and how missed

Endometriosis affects roughly one in ten women of reproductive age worldwide — around 190 million people Zondervan et al. 2020. Among women being investigated for infertility or chronic pelvic pain, the rate jumps to 30–50%. It is not a rare disease. It is roughly as common as type 2 diabetes in the same age band.

It is also one of the most consistently under-diagnosed common diseases in modern medicine. A scoping review pulling together studies from across the world found an average delay from first symptom to formal diagnosis of around six and a half years, with country-level averages stretching from under a year in Brazil to more than a decade in the UK and US Fryer et al. 2024. Most women see multiple doctors before anyone names it. The reasons are well-documented and converge across studies: severe period pain is normalised by patients and clinicians alike, symptoms get attributed first to IBS or anxiety or "stress", and until very recently the formal diagnostic standard required surgery — a high bar that meant many women were told there was nothing wrong because nobody looked.

What "normal" actually looks like

The single most damaging piece of folk wisdom about menstruation is that severe pain is part of the deal. It isn't. A period can be uncomfortable. It should not, in a healthy reproductive system, regularly require missing school or work, doubling over, vomiting, or maxing out the recommended dose of ibuprofen. Pain that interferes with daily life is the cardinal warning sign of endometriosis, and the leading medical body for adolescent gynaecology has been clear for years that this is a signal to investigate, not to wait out ACOG 2018.

The other widely-repeated claims that are wrong:

"Pregnancy cures it." Pregnancy can suppress symptoms temporarily, but lesions persist and reactivate afterwards.
"Hysterectomy cures it." Removing the uterus doesn't remove the disease — the lesions outside the uterus stay, and symptoms can continue.
"If your scan is normal, you don't have it." The thin, surface-level form of the disease — the most common kind — is largely invisible on ultrasound and MRI. A normal scan does not rule endometriosis out, and the most recent UK guideline says so explicitly NICE 2024.
"Worse-looking disease means worse pain." A tiny lesion sitting on a pelvic nerve can hurt more than a large endometrioma on an ovary. Surgical "staging" of endometriosis correlates badly with how a patient actually feels.
"It only affects adult women." Endometriosis presents in teenagers, and two-thirds of adolescents with severe period pain that doesn't respond to standard treatment turn out to have it ACOG 2018.

What untreated endometriosis costs

The default story most women with endometriosis are still living is this. The first really bad period happens in the mid-teens. A parent says periods are like that. A GP says periods are like that. Ibuprofen helps for a year, then helps less. By the early twenties she is missing one or two days of work or school every month, and the missed days are starting to be noticed by people around her. She tries to schedule social things and travel around her cycle and stops being able to. Her partner notices her cancel on plans. Her boss notices the pattern. She doesn't say what's actually going on because the language she has for it is "I get bad periods" and she's been told for ten years that this is normal.

The pain itself escalates. What started as cyclical — bad on day one, fine by day three — becomes constant in a subset of women, because the central nervous system learns the pain and starts producing it on its own, a process called central sensitisation that is genuinely harder to reverse the longer it goes on Taylor et al. 2021. Sex becomes painful. Pooing during a period becomes painful. Sometimes urinating does too. Fatigue stops being explainable by how much sleep she got. The relationship between her cycle and her mood becomes so reliable that she organises her life around it.

By the time the average woman gets a diagnosis, she has spent the better part of a decade in this. She is more likely to be depressed and anxious than her friends of the same age, and the gap is not subtle — depression and anxiety run several times above general-population baselines in women with endometriosis, mediated largely by the chronic pain itself Facchin et al. 2023. She is also more likely to be struggling at work — across ten countries, the average woman with endometriosis loses around six and a half hours of work a week to symptoms, mostly to "presenteeism" (being at her desk but unable to function), not to absence Nnoaham et al. 2011.

If she wanted children, fertility is the next thing to come up. Monthly chance of conception in women with endometriosis runs around two to ten per cent, against roughly 15–20% in fertile couples Zondervan et al. 2020. Some of this is mechanical — adhesions have pulled organs out of position — and some is biochemical, with the inflammatory environment hostile to eggs and sperm alike. Most women with endometriosis still have children if they want to, but the path is harder and shorter than they thought it would be.

The symptoms to recognise

Three patterns are worth knowing. None are diagnostic on their own; together they should trigger the conversation.

Period pain that genuinely interferes with life. Missing school or work; pain that ibuprofen barely touches; vomiting or fainting on the worst day; pain that started gentle in the teens and has been getting worse year by year.
Pain that has spread beyond the period itself. Pain during or after sex, especially deep inside rather than at the entrance. Pain when emptying the bowel or bladder, especially during the period. Pain in the same place in the pelvis between periods.
Persistent trouble getting pregnant. Around half of women with endometriosis present this way rather than with pain. If conception isn't happening after a year of trying — six months if she is over 35 — endometriosis is one of the conditions a fertility workup should be looking for.

Background risk-raisers worth flagging to a doctor: a mother, sister, or daughter with confirmed endometriosis; periods that started young (before twelve) and have always been heavy; cycles shorter than 27 days. None of these are alarms on their own — they just lower the threshold for "this is worth investigating."

If you are in your late teens or twenties and reading this for yourself: the most common version of this story is a young woman who has been told for years that her pain is normal, who only gets taken seriously once she tries to get pregnant in her thirties and can't. Going to a clinician now — with a written symptom and cycle diary, naming endometriosis specifically as a possibility you want investigated — is the highest-leverage thing you can do. If the first clinician dismisses you, the second one might not. Family-history-positive cases get diagnosed faster, partly because mothers who recognise themselves in their daughter's symptoms advocate harder.

What the diagnosis pathway actually looks like now

Until 2022, the formal way to confirm endometriosis was keyhole surgery — a laparoscopy under general anaesthetic to look inside the pelvis. That requirement is a big part of why diagnoses took so long: surgery is a high bar, and waiting lists are long. The European fertility society (ESHRE) updated its guideline in 2022 to drop the surgical requirement, and the UK's NICE guideline followed in 2024 ESHRE 2022 NICE 2024. Today, a careful symptom history and a good transvaginal ultrasound scan — done by someone trained specifically in endometriosis imaging — is enough to start treatment in most cases. MRI is reserved for cases where the disease looks deep or complicated, or where the ultrasound is unclear.

The catch: superficial endometriosis, the most common form, does not reliably show up on either scan Nisenblat et al. 2016. A clean scan does not rule the disease out. A doctor who tells a woman with classic symptoms that her ultrasound is normal and therefore she's fine is working off an outdated playbook. The current approach — and the one to ask for — is symptom-led: if the picture fits, start treatment, see if it helps, and use surgery if the medication route doesn't work or fertility is an immediate concern.

What treatment looks like

The first-line approach for pain is to suppress the menstrual cycle so the lesions stop bleeding each month. In practice that usually means a combined oral contraceptive pill taken continuously (skipping the placebo week, so periods stop), or a progestin-only treatment — daily dienogest, a hormonal IUD, or the injection. About two out of three women get meaningful pain reduction within three to six months on this approach ESHRE 2022. Anti-inflammatories (ibuprofen, naproxen) are added on top as needed.

For the third or so who don't respond, the next step is a newer class called oral GnRH antagonists — elagolix and relugolix in combination tablets. These shut off ovarian hormone production at the brain end. They work well on pain; the trade-off is hot flushes and some bone-density loss, which is why the modern versions come bundled with a small dose of replacement hormone to soften the side effects Taylor et al. 2017. Surgery — laparoscopic excision of visible lesions by an experienced endometriosis surgeon — is reserved for failed medical treatment, large endometriomas, deep disease invading the bowel or bladder, or for women trying to conceive. It works well: pain scores typically drop substantially, and a meaningful share of previously infertile women go on to conceive. The honest caveat: recurrence is real. Roughly one in four to one in five women have pain return within the first year after surgery, and rates climb over time ESHRE 2022. Continuing hormonal suppression after surgery delays recurrence.

What changes once it's treated

Most women on continuous hormonal suppression notice the difference inside one or two cycles. The first thing usually to go is the worst day of the period — the day off work, the day curled up on the bathroom floor. By three to six months, for roughly two-thirds of patients, the pain is at a level that no longer organises the week around it ESHRE 2022. For some, periods stop entirely; for some, they become a manageable inconvenience that ibuprofen can handle.

The second-order changes are the ones that surprise people. The chronic fatigue that had become a personality trait lifts. Sleep on what would have been period nights stops being broken. The brain fog that made meetings hard to follow clears. Partners notice these before the patient does. Sex stops being something to flinch from. Cancelled plans stop being a monthly occurrence. The mood comorbidities — the depression and anxiety that had been accumulating quietly for years — lift in step with the pain, not in spite of it: treating the pain is what treats the mood, not the other way around Facchin et al. 2023.

The honest framing on time horizons: pain relief is fast — weeks to months. Fertility, where it's the goal, is a separate negotiation — sometimes pregnancy follows surgery without further help; sometimes IVF is part of the plan; outcomes are good for mild-to-moderate disease and lower for severe. The long-run trajectory of the disease itself is a maintenance picture, not a cure. Women on continuous suppression stay on it until they want to conceive or until menopause closes the chapter naturally. Recurrence after surgery is real and routine. None of which is a reason to leave the disease unmanaged for another decade — it is a reason to start managing it now, with the expectation that this is a long relationship with a chronic condition, not a one-shot fix.

Adjacent topics worth knowing about: adenomyosis, a related condition where endometrial tissue grows into the muscle wall of the uterus itself rather than outside it (the symptoms overlap; the two often coexist). Polycystic ovary syndrome (PCOS), a different reproductive-hormone disorder that shares some symptoms (cycle disruption, fertility issues) but is mechanistically unrelated. Chronic pelvic pain from non-endometriosis causes — interstitial cystitis, pelvic-floor dysfunction, pudendal neuralgia — which can co-exist with endometriosis and need separate treatment. Pelvic-floor physical therapy as an adjunct for women whose muscles have learned to brace against pain. For women whose endometriosis is severe enough to drive infertility, the broader fertility workup and IVF conversation sits next to this one.

Related in the handbook

Helps

— Suppressing the cycle with hormonal contraception is usually the first-line move against the pain.
— Years of pelvic pain train the pelvic floor to clench; PT often eases the pain that lingers even after the lesions are treated.

— Tracking pain against the cycle is one of the cheapest ways to shorten endometriosis's long road to diagnosis.
— Adenomyosis is the close cousin — same painful, heavy periods, often coexisting; an ultrasound starts telling them apart.
— Heavy, soak-through periods often travel with endometriosis — both are reasons severe symptoms deserve a workup, not a shrug.
— Endo on the bowel mimics IBS - bloating, pain, bathroom changes. Many women carry an IBS label for years before the real cause is found.
— Fibroids are another common cause of heavy, painful periods — worth ruling in or out alongside endometriosis.

Substance and claimed effects

Endometriosis is a chronic, oestrogen-dependent inflammatory disease in which endometrial-like glands and stroma — tissue resembling the lining of the uterus — implant, vascularise, and bleed cyclically at sites outside the uterine cavity. Classic locations are the pelvic peritoneum, ovaries (where lesions form chocolate-coloured cysts called endometriomas), the uterosacral ligaments, the rectovaginal septum, the bladder serosa, and the rectosigmoid bowel; rare extrapelvic sites include diaphragm, thoracic cavity, and abdominal wall scars Zondervan et al. 2020. Estimated prevalence is roughly 10% of reproductive-age women — about 190 million globally — rising to 30–50% among women presenting with infertility or chronic pelvic pain Zondervan et al. 2020 Taylor et al. 2021. Claimed consequences this entry covers holistically: severe dysmenorrhoea (the cardinal symptom), chronic non-cyclical pelvic pain, deep dyspareunia, cyclical bowel and bladder symptoms (dyschezia, dysuria, haematuria), subfertility, chronic fatigue, and a substantial mental-health and quality-of-life burden — all compounded by a globally reported diagnostic delay averaging 6.6–10 years Fryer et al. 2024. A modest but real elevation in risk of clear-cell and endometrioid ovarian carcinoma is the principal longevity consequence Pearce et al. 2012.

Evidence by addressing question

Mechanism

The dominant aetiological model remains Sampson's 1927 retrograde-menstruation hypothesis: viable endometrial fragments reflux through the fallopian tubes during menses, implant on peritoneal surfaces, and respond to ovarian steroid cycling at the ectopic site Sampson 1927. Recent molecular work supports the model — identical somatic mutations (notably KRAS and PIK3CA) have been mapped between eutopic endometrium and ectopic implants in the same patient, consistent with a clonal eutopic-to-ectopic seeding event Saunders & Horne 2021. The model is, however, incomplete: roughly 90% of cycling women have retrograde menstruation but only ~10% develop disease, so additional factors — altered peritoneal immune surveillance, NK-cell dysfunction, macrophage polarisation, local oestrogen synthesis via aromatase upregulation in lesions, progesterone resistance, and a heritable component — are needed to explain disease establishment Zondervan et al. 2020 Saunders & Horne 2021. Coelomic metaplasia (peritoneal cells transforming into endometrium-like tissue) and lymphovascular dissemination explain rare locations the Sampson mechanism cannot reach (thoracic and umbilical disease, premenarchal cases). Pain pathophysiology is multi-layered: prostaglandin-driven nociception from cyclic bleeding within lesions, infiltration of small unmyelinated nerve fibres into lesions, central sensitisation of pelvic pain pathways, and adhesion-related visceral tethering Taylor et al. 2021. Disease is conventionally classified into three phenotypes — superficial peritoneal, ovarian endometrioma, deep infiltrating endometriosis (DIE, depth >5 mm) — and staged I–IV by the revised ASRM system, which correlates poorly with symptom severity.

Evidence (does it actually happen)

The condition's existence and natural history are not in dispute — peritoneal lesions are histologically confirmable; epidemiology is well-characterised at population scale from registry data and from operative cohorts. A Global Burden of Disease 2021 analysis identifies endometriosis as a major contributor to female disability-adjusted life-years (DALYs) in the 20–44 age band, peaking in incidence at ages 20–24 Zondervan et al. 2020. Heritability is approximately 50% from the Australian classical twin study (n=3,096 twins; concordance for monozygotic twins ~52%; for dizygotic ~19%) Treloar et al. 1999, with the largest GWAS meta-analysis (n=60,674 cases; 701,926 controls) identifying 42 risk loci and showing genetic overlap with chronic pain conditions, migraine, IBS, and inflammatory disease Rahmioglu et al. 2023. First-degree relatives have approximately 5–7× the population risk. Symptom severity correlates inconsistently with anatomical disease burden — superficial disease can cause severe pain; extensive DIE can be relatively asymptomatic — an observation that has driven the field away from staging-based prognosis toward symptom-based management.

Practice (diagnosis pathway)

Until 2022, laparoscopy with histological confirmation was the formal diagnostic gold standard. The current ESHRE guideline, mirrored by NICE NG73 (updated 2024), no longer requires laparoscopy: clinical history plus imaging (transvaginal ultrasound first-line, MRI for complex or deep disease) is sufficient to initiate empirical treatment ESHRE 2022 NICE 2024. Critically, a normal scan does not rule out endometriosis — superficial peritoneal disease, the commonest phenotype, is largely invisible on imaging. Cochrane meta-analysis: transvaginal ultrasound for ovarian endometrioma has pooled sensitivity ~93% and specificity ~95%; for deep rectosigmoid endometriosis, sensitivity is 79–94% (operator-dependent), specificity 84–95% Nisenblat et al. 2016. MRI offers broader anatomical coverage (especially anterior compartment / bladder) but is more expensive and less universally available; sensitivities for DIE 80–95%, specificities 85–95%. CA-125 lacks adequate specificity for diagnosis. The shift away from mandatory laparoscopy was the most consequential change in modern endometriosis practice — it removes a major barrier to early treatment and was the field's response to the diagnostic delay problem.

Practice (treatment)

First-line pharmacotherapy for pain is NSAIDs plus a continuous hormonal suppressive: combined oral contraceptive pills (taken continuously to suppress menses) or a progestin-only agent (oral dienogest 2 mg/day, depot medroxyprogesterone, or the 52 mg levonorgestrel intrauterine system) ESHRE 2022 NICE 2024. Roughly one-third of patients have inadequate response, often attributed to progesterone resistance in endometriotic lesions. Second-line: GnRH agonists (leuprolide depot) and the newer oral GnRH antagonists elagolix (FDA-approved 2018) and relugolix combination therapy (FDA-approved 2022). The pivotal elagolix trials (Elaris EM-I and EM-II) showed a clinically meaningful reduction in dysmenorrhoea and non-menstrual pelvic pain at 150 mg daily and 200 mg twice daily over 6 months, with the higher dose more effective but with greater hypo-oestrogenic adverse effects and measurable bone mineral density loss Taylor et al. 2017. Relugolix combination therapy bundles add-back oestradiol/norethindrone to preserve bone density and is approvable for longer-term use. Surgical excision (laparoscopic, by an experienced endometriosis surgeon, ideally with multidisciplinary input for bowel/urinary involvement) is indicated for failed medical therapy, large endometriomas, suspected deep infiltrating disease, or fertility goals; complete excision provides better symptom durability than ablation, but pain recurrence rates remain 20–26% in the first year and 43–50% at 5 years, and lesion recurrence runs 12–29% at 1–2 years ESHRE 2022. Hysterectomy with bilateral salpingo-oophorectomy is definitive for women who have completed childbearing and failed conservative management, but is not curative — residual peritoneal lesions can persist and progress on hormone replacement therapy if introduced. For endometriosis-associated infertility, IVF outcomes are typically comparable to other infertility populations in stage I–II disease but lower in stage III–IV; pre-IVF GnRH-agonist suppression for 3–6 months improves clinical pregnancy rates in some trials. Ablative bowel/bladder surgery is technically demanding and centre-volume-dependent; complication rates are non-trivial.

Community / lay evidence

The community signal — from patient advocacy organisations (Endometriosis UK, Endometriosis Foundation of America), large online communities (r/Endo, Reddit), and patient surveys — converges remarkably consistently on three themes that the academic literature has now formally adopted: (1) symptoms are routinely dismissed as "normal period pain" by clinicians and family for years; (2) the diagnostic odyssey involves multiple doctors and misdiagnosis as IBS, ovarian cysts, "anxiety", or PID; (3) patients commonly report cognitive symptoms ("endo brain"), fatigue, and mental-health impacts disproportionate to anatomical disease. The community-vs-establishment tension here is not about whether the disease exists (it does) but about whose pain reports are taken seriously and at what threshold. The 2024 NICE update and the 2022 ESHRE guideline both explicitly cite patient experience and the diagnostic-delay literature as drivers of the move to imaging-based / symptom-based diagnosis — a relatively rare case of advocacy reshaping international guidelines within a decade.

Historical

Lesions resembling endometriosis have been described in autopsy reports since the 17th century; the modern conceptual framework dates to John Sampson's three foundational papers (1921, 1925, 1927), which established the chocolate-cyst phenotype, named the disease, and proposed retrograde menstruation as the seeding mechanism Sampson 1927. For most of the 20th century, endometriosis was managed as a surgical disease; the development of GnRH agonists in the 1980s shifted the field toward medical suppression. The reframing as a chronic inflammatory systemic disease — rather than a purely gynaecological lesional disorder — is recent and ongoing Taylor et al. 2021.

Stakes (untreated trajectory)

The natural history without treatment is heterogeneous: some lesions stabilise, some regress (particularly at menopause), and some progress, with deep infiltrating disease tending to be the most progressive phenotype. Untreated, the clinical sequelae are: cumulative menstrual cycles of escalating pain that progress from cyclical to constant in a subset; pelvic adhesion formation distorting reproductive anatomy; subfertility — monthly fecundity drops to ~2–10% versus 15–20% in fertile couples Zondervan et al. 2020; central sensitisation of pelvic pain pathways making later treatment less effective; opioid dependence in a subset who never obtain adequate management; and the documented mental-health toll — depression prevalence in endometriosis cohorts spans 10–98% across studies (heterogeneity reflects measurement variation) but is consistently elevated above general-population baselines, with the relationship partly mediated by chronic pain and partly by direct inflammatory effects on the CNS Facchin et al. 2023. The economic stakes are large: real-world US claims data put direct annual healthcare costs at ~$12,000/patient and indirect (productivity-loss) costs at ~$16,000/patient, with presenteeism dominating over absenteeism Souliman et al. 2019; the 10-country WERF EndoCost study found an average of 6.4 hours of weekly work lost Nnoaham et al. 2011. Diagnostic delay is itself a stakes multiplier — every additional year before diagnosis worsens pain trajectory and increases lifetime healthcare cost Fryer et al. 2024.

Payoff (treated trajectory)

Early, properly-titrated continuous hormonal suppression achieves substantial pain reduction in roughly two-thirds of patients within 3–6 months ESHRE 2022. Surgical excision in expert hands reduces pain scores from severe (VAS ~6.8) to mild (VAS ~1.5) post-operatively in cohort studies, with 78% of previously infertile women conceiving subsequently in one series. The mental-health and quality-of-life trajectory tracks pain reduction — symptom alleviation is the lever; "treating depression alongside endometriosis" without addressing the pain misses the dominant mediator. The realistic payoff frame: pain controlled, periods made bearable or absent, fertility preserved when desired, and the diagnostic-odyssey years recovered. Not "cure" — recurrence is real and lifelong management is the norm — but a transformed trajectory.

Misconceptions

The widely-repeated claims that are wrong: (1) "Severe period pain is normal" — it isn't; pain that interferes with school, work, or daily life warrants investigation ACOG 2018. (2) "Pregnancy cures endometriosis" — pregnancy may suppress symptoms temporarily but is not curative; lesions persist and reactivate. (3) "Hysterectomy is a cure" — hysterectomy without removing peritoneal disease is not curative; symptoms recur if extra-uterine lesions remain. (4) "If imaging is normal, you don't have endometriosis" — superficial peritoneal disease is largely invisible on ultrasound and MRI; the 2024 NICE update explicitly states a normal scan does not exclude disease NICE 2024. (5) "Stage IV disease means worse pain than Stage I" — staging correlates poorly with symptoms; a tiny superficial lesion on a nerve root can cause severe pain. (6) "Endometriosis is just a fertility issue / just a pain issue" — both framings undersell the systemic nature: chronic inflammation, fatigue, cognitive effects, mood comorbidity are part of the disease, not separate problems Taylor et al. 2021. (7) "It only affects adult women" — endometriosis presents in adolescents; ACOG and ESHRE both call for early evaluation when dysmenorrhoea is unresponsive to NSAIDs plus hormonal trial ACOG 2018.

Contraindications and special cases

Combined oral contraceptive contraindications (smoker over 35, history of VTE, migraine with aura, uncontrolled hypertension) push therapy toward progestin-only regimens. GnRH agonists/antagonists are limited by hypo-oestrogenic effects: vasomotor symptoms, bone mineral density loss (a particular concern in adolescents whose peak bone mass is still being built — ESHRE recommends add-back therapy if used >6 months in this population). Surgery for deep infiltrating disease involving bowel or ureter is high-risk and should be done at high-volume centres with multidisciplinary teams. Pregnancy and breastfeeding obviously alter management. Postmenopausal endometriosis is uncommon but real; hormone replacement therapy in women with prior endometriosis carries some risk of lesion reactivation.

Audience (who specifically)

Reproductive-age women (15–49) are the principal at-risk group, with peak symptom onset in late teens to early thirties. Adolescents are a key under-served subgroup — dysmenorrhoea is the leading cause of school absence among adolescent girls, and at least two-thirds of adolescents presenting with dysmenorrhoea unresponsive to NSAID + hormonal therapy are diagnosed with endometriosis at laparoscopy ACOG 2018. Adolescent lesions are typically clear or red and easily missed by inexperienced surgeons. Family-history-positive women (first-degree relative with confirmed disease) carry roughly 5–7× population risk and warrant a lower threshold for evaluation. Trans-masculine individuals with retained uteri are also affected and frequently under-served by gendered care pathways. Race-based disparities in diagnosis and care access are documented but the underlying biology does not appear to track race; the gap is healthcare-system-driven.

Out of scope

Adenomyosis (endometrial tissue within the uterine myometrium) is biologically and clinically related but distinct; it shares symptoms and treatments but warrants its own entry. Chronic pelvic pain from non-endometriosis causes (interstitial cystitis, pudendal neuralgia, pelvic floor dysfunction) overlaps clinically but is mechanistically separate. Detailed surgical technique (excision vs. ablation, nerve-sparing approaches) is out of scope for a reader-facing entry. Dietary and complementary interventions (anti-inflammatory diet, acupuncture, pelvic-floor physical therapy) have weak-to-moderate evidence and are reasonably included as adjuncts but not first-line.

Credibility range

Optimist case

Endometriosis is one of the better-characterised chronic women's-health diseases. Pathology is histologically definable; epidemiology is consistent across continents; heritability is established; effective pharmacotherapy exists with multiple mechanistically distinct classes; surgical techniques have matured; imaging-based diagnosis now allows treatment to start without surgery. The 2022 ESHRE and 2024 NICE guideline updates removing the laparoscopy gatekeeping requirement is a structural reform that will compress diagnostic delay over the coming decade. New oral GnRH antagonists with add-back therapy give patients an option that did not exist five years ago. A first-degree relative is enough to flag the genetic component; a careful symptom history plus a competent transvaginal ultrasound can now diagnose most cases. The disease is real, treatable, and the trajectory of the field is positive.

Skeptic case

The pathogenesis remains incompletely understood — Sampson's hypothesis cannot fully explain why 10% of women develop persistent disease while 90% with retrograde menstruation do not, and competing theories (coelomic metaplasia, stem-cell migration, Müllerian remnants) suggest endometriosis may be a heterogeneous group of conditions rather than a single entity, which would explain the inconsistent treatment response across patients. Hormonal therapies suppress symptoms but do not eliminate lesions; surgery has high recurrence rates (43% pain recurrence at 5 years); no treatment is curative, and many patients cycle through years of medications and multiple operations with incomplete relief. The diagnostic-delay literature is real, but average-delay statistics conceal vast geographic and socio-economic heterogeneity. Mental-health comorbidity studies show prevalence ranges so wide (depression 9.8–98.5%) that pooled estimates are barely interpretable. The new oral antagonists are expensive and bone-density effects in long-term use remain incompletely characterised. The shift to imaging-based diagnosis risks misdiagnosis of superficial disease that imaging cannot see — empirical hormonal therapy in young women without confirmed disease is medication exposure with side effects. The condition is real but the field's enthusiasm runs ahead of the evidence for many specific protocols.

Author's call

The optimist case carries. Endometriosis is real, common, under-diagnosed, and the evidence base for hormonal first-line therapy and excisional surgery is solid enough that the public-health priority is clearly to compress diagnostic delay and route symptomatic women into treatment faster — not to debate pathogenesis from the sidelines while patients suffer for a decade. The skeptic case is correct on specifics (heterogeneity within the disease, imperfect treatment durability, mental-health-prevalence noise) but those are reasons to refine management, not to under-treat. The entry should be calibrated: high evidence on the existence and burden of the disease and on first-line treatment efficacy; moderate-to-low controversy on management; honest about treatment limitations (recurrence is real, cure is rare); strong emphasis on the awareness/recognition pathway because that is the highest-leverage point — most readers will not have endometriosis themselves but may recognise it in a partner, sister, or daughter, and the entry's job is to put the symptom pattern into their head and lower the threshold for taking it seriously.

Stakeholder and incentive map

Patient advocacy organisations (Endometriosis Foundation of America, Endometriosis UK, Endo What?, EndoBlack) have been the loudest force pushing diagnostic-delay reform and guideline change; aligned with patient interest, financially modest.
Specialty surgical centres have a financial and reputational stake in being recognised as expert excision providers; have driven the excision-over-ablation debate and the move to multidisciplinary endometriosis units.
Pharmaceutical industry (AbbVie / Neurocrine for elagolix; Myovant / Pfizer for relugolix combination therapy; Bayer for dienogest) has commercial interest in expanding the prescribed market beyond first-line oral contraceptives; trial design and post-marketing emphasis reflects this.
Guideline bodies (ESHRE, NICE, ACOG, AAGL) have aligned the field on imaging-based diagnosis and individualised symptom-based treatment, with relative consensus across the major bodies.
General gynaecology practice historically under-served endometriosis — many practising gynaecologists are not specialists in this condition, and the under-recognition pattern is partly a workforce-training gap.
General practitioners and emergency departments are typically the patient's first point of contact and historically the strongest barrier to timely diagnosis; the diagnostic-delay reform efforts target this layer.
Skeptic / counter-incentive: insurance payers in some systems have under-recognised endometriosis (the 1% prevalence figure that appears in some insurer data is implausibly low), creating financial incentive to limit specialty referral.

Population variability

Age: incidence peaks at 20–24; symptom onset commonly in late teens; postmenopausal disease is uncommon but possible. Adolescent presentation under-recognised.
Family history: first-degree relative with confirmed disease raises risk ~5–7×; familial cases tend to be more severe and present earlier Treloar et al. 1999.
Reproductive factors: early menarche, short cycles, heavy menstrual flow, nulliparity increase risk (more lifetime menses = more retrograde events). Higher parity and prolonged breastfeeding are weakly protective.
BMI: low BMI weakly associated with higher risk; high BMI weakly protective; effect is modest.
Race / ethnicity: historical literature suggested higher prevalence in Asian women and lower in Black women, but recent work suggests this reflects diagnostic-access disparity rather than true biological difference. Black women in the US face longer diagnostic delays.
Subtypes: superficial peritoneal, ovarian endometrioma, and deep infiltrating endometriosis respond differently to treatment; DIE is the most likely to require surgical intervention.
Trans-masculine patients with retained uteri are an under-served subgroup.

Knowledge gaps

Pathogenesis: why only ~10% of women with retrograde menstruation develop persistent disease remains unanswered; immune, genetic, and microbiome contributions are partially mapped but not integrated.
Non-invasive biomarker: no validated blood or imaging biomarker reliably detects superficial peritoneal disease; this remains the largest practical research gap.
Natural history: longitudinal data on which lesions progress, stabilise, or regress are sparse — the field cannot yet predict trajectory at diagnosis.
Pain phenotyping: why symptoms correlate so poorly with anatomical stage is incompletely explained; central sensitisation and nerve-fibre infiltration are part of the answer but not the whole.
Long-term safety of oral GnRH antagonists in extended use, including in adolescents, is still accumulating.
Surgical durability: which patients will recur and when remains unpredictable.
Mental-health pathway: how much of the depression/anxiety signal is mediated by pain versus by direct inflammatory effects on the CNS is an active question.
Adolescent disease: appearance and progression of early lesions, and whether early intervention prevents progression to DIE, are under-studied.

Scope and framing. Written as a know entry oriented toward the broad reader — partner, sister, daughter, friend — rather than as a clinical management piece for the diagnosed patient. The highest-leverage intervention for this condition is compressing the diagnostic delay; the article is engineered around that lever.

Coverage relative to the brief. The brief named pelvic pain, dysmenorrhoea, fertility, bowel and bladder symptoms, and the diagnostic delay. All five are covered: the diagnostic delay is the spine of the dek and the stakes section; dysmenorrhoea and pelvic pain run through stakes, audience symptoms, and payoff; fertility is treated in stakes and in the symptoms-to-recognise list; bowel and bladder symptoms appear in the symptom checklist and in the practicalities section (deep disease referral cue). Mental-health comorbidity and the ovarian-cancer association were added on top of the brief — both warrant the inclusion given the strength of the evidence.

Rating calls.

health_short_term: 4 rather than 5 — for the subset who recognise the pattern and get treatment, the lift is genuinely transformative, but the entry's reach extends to readers without the condition, so a 5 ("dominant effect that defines the entry") felt over-claimed against the unaffected majority.
mood: 4 — the depression/anxiety signal in cohort studies is large but the heterogeneity is also large (9.8%–98.5% range). Landed at 4 rather than 5 because effective psychiatric intervention is a stretch comparison; the mechanism is pain mediation, not direct mood treatment.
longevity: 1 — Pearce 2012 pooled analysis is solid for the relative-risk doubling on clear-cell and endometrioid subtypes, but absolute lifetime risk stays low. A 2 felt over-weighted given the rarity of those histotypes.
controversy: 2 — kept low because the major guideline bodies (ESHRE, NICE, ACOG) agree on the management approach. The pathogenesis debate is real but not at the level of "the field is split on what to do."
evidence: 5 — multiple international guidelines, large RCTs for newer agents, twin/GWAS heritability replication, Cochrane meta-analysis on imaging. Comfortable at the top of the scale.

Deliberately excluded.

Detailed surgical technique (excision vs. ablation, nerve-sparing approaches, bowel resection technique) — relevant to the patient already in the surgical pathway, not to the awareness-pathway reader.
Dietary and complementary interventions (anti-inflammatory diet, acupuncture) — evidence is weak-to-moderate and the entry is already long; they belong in a follow-on entry or in adjunct-therapy callouts on the practicalities section in a future revision.
Disease staging (rASRM I–IV, the ENZIAN classification) — included implicitly in the misconception that stage tracks pain, but not laid out as a system; clinical taxonomy adds load without changing the reader's action.
Detailed pathogenesis debates (coelomic metaplasia, Müllerian remnants, stem-cell models) — flagged in the dossier but kept out of reader prose to avoid burying the practical message under aetiological argument.

Separate-entry candidates surfaced during the write.

Adenomyosis — clinically and biologically adjacent, distinct enough to warrant its own entry. Forward-pointer placed in the closing section.
Dysmenorrhoea as a general entry covering primary dysmenorrhoea and the differential with secondary causes — would naturally pair with this entry.
Chronic pelvic pain as a syndrome-level entry covering non-endometriosis causes.
Hormonal contraception as a standalone entry — the entry leans on continuous COC as first-line treatment but does not unpack contraceptive choice; that work belongs elsewhere.

Future-link candidates. Once written, this entry should cross-link to: adenomyosis, primary dysmenorrhoea, fertility workup, IVF, pelvic-floor physical therapy, and (if a screening entry on ovarian cancer is built) the clear-cell/endometrioid risk pathway. Audience-block in the symptoms section assumes a future late-teens/twenties entry on advocating for yourself at the GP — currently absent.

Rating difficulties. Scoring a know entry against benefit dimensions is awkward — the dimensions are calibrated against substances that do something to a user, whereas this entry's mechanism is "recognise the pattern, then act." Landed by scoring against the felt-effect trajectory of a diagnosed and treated patient, with a calibrated downshift to reflect that the entry serves a broader audience than just affected women. Worth a guideline pass on how to score awareness-pathway entries — the current per-dimension anchors implicitly assume an actionable intervention.

Language and tone. Kept a calm, factual register throughout, avoiding the wellness-influencer "you deserve answers" register that this topic often attracts. The stakes section reaches for felt-experience anchors (cancelled plans, the way a partner notices, the bathroom-floor day) without overshooting into trauma-narrative territory. The audience block addresses the late-teens/twenties reader directly because the highest-leverage intervention for that cohort is acting now rather than in their thirties.